Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Royalty (NASDAQ: XOMA) announced it completed its tender offer and acquisition of Generation Bio (NASDAQ: GBIO). Generation Bio stockholders received $4.2913 per share in cash plus one non-tradeable contingent value right (CVR). Approximately 4,722,533 shares (~70%) were validly tendered. Following the tender, XRA 7 Corp. merged into Generation Bio, which became a wholly owned subsidiary of XOMA Royalty. Trading in Generation Bio common stock ceased on Nasdaq after market close on February 6, 2026, and the companies intend to delist and deregister those shares.
XOMA Royalty (Nasdaq: XOMA) announced on January 12, 2026 that Chief Financial Officer Thomas Burns will step down to pursue other opportunities after nearly two decades with the company. The board thanked Burns for his leadership during XOMA Royalty’s transition to a royalty aggregator and for building a strong financial foundation. The company appointed Jeffrey Trigilio as CFO; he previously served as CFO and COO at Obsidian Therapeutics and as CFO at Cullinan Therapeutics, and began his career at Alexion Pharmaceuticals. Management emphasized continued disciplined capital deployment, diligence, and deal structuring to grow the royalty portfolio and deliver value for shareholders.
XOMA Royalty (NASDAQ: XOMA) and Takeda amended their 2006 collaboration via a strategic royalty share transaction announced Dec 30, 2025. Takeda regains a majority of XOMA Royalty’s mezagitamab economics while XOMA Royalty will retain a low single-digit royalty on mezagitamab and up to $13.0 million in milestones (previously mid-single-digit royalty and $16.25 million in potential milestones).
In exchange, XOMA Royalty will receive payments (low to mid-single-digit royalties and milestones) tied to a basket of nine development-stage assets from Takeda’s externalized portfolio, including programs from Neurocrine, Mirum, Oak Hill Bio, Recursion, and others.
XOMA Royalty (Nasdaq: XOMA) declared quarterly cash dividends for its preferred shares on Dec 22, 2025. The Board authorized a dividend of $0.53906 per share for the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) and $0.52344 per depositary share for depositary shares representing 1/1000 of the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO).
Both preferred dividends are payable on or about Jan 15, 2026 to holders of record at the close of business on Jan 2, 2026.
XOMA Royalty (Nasdaq: XOMA) announced it has completed the acquisition of Mural Oncology (Nasdaq: MURA) by way of an Irish High Court sanctioned scheme of arrangement.
Mural shareholders received $2.035 cash per share as the consideration. The scheme was sanctioned by the Irish High Court on December 3, 2025 and became effective on December 5, 2025 upon delivery of the court order to the Irish Companies Registration Office.
Prior to trading on December 5, 2025, Mural shares will cease trading on Nasdaq and Mural intends to seek prompt delisting and deregistration under the Securities Exchange Act of 1934.
XOMA Royalty (Nasdaq: XOMA) announced on Nov 21, 2025 it has completed its acquisition of all outstanding common shares of LAVA Therapeutics (Nasdaq: LVTX). LAVA shareholders received $1.04 cash per share plus a non-transferable contingent value right (CVR) that may pay up to ~$0.23 per CVR depending on post-closing liability determinations. Approximately 23,956,708 shares (91.1%) were tendered by the final expiration date; XOMA Royalty acquired 100% of LAVA’s successor via a corporate reorganization. Trading of LAVA shares was suspended before Nov 21, 2025, and LAVA intends to delist and deregister its shares.
Deal highlights: two partnered bispecific antibody programs with Johnson & Johnson and Pfizer; cash consideration and CVR structure for shareholders.
XOMA Royalty (NASDAQ: XOMA) reported third-quarter and year-to-date 2025 results on November 12, 2025, highlighting portfolio-building acquisitions, partner clinical readouts, and cash receipts. In the first nine months of 2025 XOMA received $43.9M from partners ($30.3M royalties, $13.6M milestones/fees) and $14.3M in Q3 royalties. Income and revenue were $9.4M (Q3) and $38.4M (YTD). Net income was $14.1M (Q3) and $25.6M (YTD). Cash and equivalents totaled $130.6M on September 30, 2025, including $85.4M restricted cash. Recent acquisitions include Turnstone, HilleVax, announced LAVA and Mural deals; several partner Phase 3 readouts are anticipated through mid-2026.
XOMA Royalty (Nasdaq: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) amended their share purchase agreement on October 17, 2025.
Under the Amendment, tendering LAVA shareholders will receive an initial cash amount of $1.04 per share plus a non-transferable CVR that preserves rights to 75% of net proceeds from partnered assets and unpartnered program exits, and a new contingent right of up to $0.23 per CVR depending on final liability determinations. LAVA’s minimum net-cash closing condition was reduced to $24.5 million (from $31.5 million). The Offer deadline extended to Nov 12, 2025 and closing is expected in Q4 2025, subject to tender thresholds and shareholder approvals.
XOMA Royalty (NASDAQ: XOMA) and LAVA Therapeutics (Nasdaq: LVTX) extended the expiration of their tender offer to acquire all outstanding LAVA shares until one minute after 11:59 p.m. ET on October 17, 2025. The Offer pays a cash amount (per the Purchase Agreement) plus a non-transferable CVR per share granting holders 75% of net proceeds from LAVA’s two partnered assets and 75% of net proceeds from any out-license or sale of unpartnered programs. Closing is expected in Q4 2025, subject to conditions including at least 80% (or 75%) tendered shares, shareholder approvals, a minimum cash balance at closing, and other customary conditions. LAVA shareholders have signed support agreements; a shareholder meeting is planned before early November 2025.
ESSA Pharma (NASDAQ: EPIX) has announced amendments to its Business Combination Agreement with XenoTherapeutics. Under the revised terms, ESSA shareholders are expected to receive approximately $0.12 per share in cash at closing, plus one non-transferable contingent value right (CVR) worth up to $0.14 per share.
The potential CVR payments represent up to $6.7 million in aggregate distributions to CVR holders, depending on contingent liabilities. This follows an initial cash distribution of approximately $1.69 per share made on August 22, 2025. The Special Meeting to approve the transaction has been adjourned to October 3, 2025, with XOMA Royalty (NASDAQ: XOMA) continuing as the structuring agent.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
